Singapore Clinical Trial: Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children with Achondroplasia

Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children with Achondroplasia'. The following are the other relevant details related to the trial:

Therapeutic Area: Other (Paediatric Medicine)

Trial Centre(s): KK Women's & Children's Hospital

Trial Status: Ongoing, Recruiting

Principal Investigator(s): Dr Goh Lay Kuan Jeannette

Published by HT Digital Content Services with permission from Health Daily Digest....